z-logo
Premium
Effects of a Grapevine Shoot Extract Containing Resveratrol and Resveratrol Oligomers on Intestinal Adenoma Development in Mice: In Vitro and In Vivo Studies
Author(s) -
Empl Michael T.,
Cai Hong,
Wang Shan,
Junginger Johannes,
Kostka Tina,
HewickerTrautwein Marion,
Brown Karen,
Gescher Andreas J.,
Steinberg Pablo
Publication year - 2018
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201700450
Subject(s) - resveratrol , in vivo , in vitro , shoot , biology , chemistry , biochemistry , botany , microbiology and biotechnology
Scope Evidence suggests that the dietary consumption of plant extracts containing polyphenols might help prevent the onset of cancers of the gastrointestinal tract. In the present study, the chemopreventive and antiproliferative efficacy of a grapevine shoot extract (Vineatrol®30) containing resveratrol and resveratrol oligomers is investigated in vivo and in vitro. Methods and results The in vivo study is performed using Apc Min mice on a high‐fat diet, which represents a model of human adenomatous polyposis, while the potential of the extract as well as some of its isolated constituents to inhibit intestinal adenoma cell proliferation in vitro is investigated using APC10.1 cells derived from an Apc Min mouse. Vineatrol®30 at a low (2.3 mg kg –1  diet) or high dose (476 mg kg –1  diet) reduces the adenoma number in male and adenoma volume in female animals. Furthermore, Vineatrol®30 as well as resveratrol and two resveratrol tetramers compromise the expansion of APC10.1 cells by reducing cell number, inducing cell cycle arrest, cellular senescence, and apoptosis. However, except for the extract, none of the isolated resveratrol oligomers is more efficacious than resveratrol in these cells. Conclusion Vineatrol®30 may merit further investigation as a potential dietary gastrointestinal cancer chemopreventive agent in humans.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here